Document is current

Article History

Received: 4 September 2024

Accepted: 13 March 2025

First Online: 10 April 2025

Declarations

:

: The DAMAGE study was performed in compliance with the tenets of the Declaration of Helsinki and was approved by an institutional review board (CPP Nord-Ouest IV, Lille, France) on February 13th, 2015. An amendment was approved on January 21st, 2016 (reference: IDRCB 2014 A01670 47, CNIL. bxA15352514). The patients and their primary family caregivers or legal representatives were given detailed verbal and written information about the study, in order to ensure that the patients fully understood the potential risks and benefits of participation. In accordance with the French legislation on observational, non-interventional studies of routine clinical care, written consent was not required. The patients were informed that they could refuse to participate in the study and that refusal would not have any impact on their treatment in the AGU. If the patient was unable to refuse to participate in the DAMAGE study (notably because of severe neurocognitive disorders), the next of kin or legal representative could refuse participation. All participants were free to withdraw from the study at any time. This withdrawal had no impact on the care received.

: Not applicable.

: The authors declare no competing interests.